CG Oncology, Inc. (CGON)
| Market Cap | 4.74B +134.0% |
| Revenue (ttm) | 5.07M +666.0% |
| Net Income | -186.75M |
| EPS | -2.35 |
| Shares Out | 88.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 951,497 |
| Open | 55.85 |
| Previous Close | 56.09 |
| Day's Range | 53.52 - 56.78 |
| 52-Week Range | 23.65 - 75.50 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 90.29 (+68.08%) |
| Earnings Date | May 8, 2026 |
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with... [Read more]
Financial Performance
In 2025, CG Oncology's revenue was $4.04 million, an increase of 254.70% compared to the previous year's $1.14 million. Losses were -$161.00 million, 82.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price target is $90.29, which is an increase of 68.08% from the latest price.
News
CG Oncology Transcript: Jefferies Global Healthcare Conference 2026
Cretostimogene is advancing as a differentiated oncolytic immunotherapy for NMIBC, showing strong durability and safety data, with a rolling BLA submission underway and commercial preparations progressing. Key upcoming milestones include pivotal trial data and expansion into broader patient populations.
CG Oncology to Present at Upcoming Investor Conferences in June
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentatio...
CG Oncology announces departure of president, COO Ambaw Bellete
In a regulatory filing, CG Oncology (CGON) announced that on May 20, the company and Ambaw Bellete, the company’s President & COO, agreed to his separation from the company to…
Wolfe sees CG Oncology COO exit as operational, no impact to key programs
Wolfe Research notes that CG Oncology (CGON) announced the departure of the company’s COO Ambaw Bellete this morning. The departure sounds more operational in nature and is not indicative of…
CG Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026
Recent data show cretostimogene plus gemcitabine offers higher efficacy and strong safety in BCG-exposed NMIBC, informing a phase III trial. Manufacturing and regulatory progress support a BLA filing by year-end, with launch readiness and broad clinical integration underway.
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year's awa...
CG Oncology initiated with a Peer Perform at Wolfe Research
Wolfe Research initiated coverage of CG Oncology (CGON) with a Peer Perform rating. CG Oncology faces key upcoming catalysts from its PIVOT-006 Phase 3 readout in intermediate-risk Non-Muscle Invasive...
CG Oncology reports first results from CORE-008 Cohort CX
CG Oncology (CGON) announced first results from CORE-008 Cohort CX, a Phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent ...
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
CG Oncology price target raised to $82 from $77 at Truist
Truist raised the firm’s price target on CG Oncology (CGON) to $82 from $77 and keeps a Buy rating on the shares. The firm notes that following its recent discussions…
CG Oncology Transcript: Bank of America Global Healthcare Conference 2026
Healthpeak completed the Janus carve-out and IPO, unlocking value and positioning both REITs for growth. Outpatient medical and lab real estate remain core, with strong demand, strategic acquisitions, and robust cash flow. Janus is set for rapid expansion, leveraging favorable senior housing trends.
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-
CG Oncology price target raised to $81 from $79 at RBC Capital
RBC Capital raised the firm’s price target on CG Oncology (CGON) to $81 from $79 and keeps an Outperform rating on the shares after its Q1 results and the firm’s…
CG Oncology price target raised to $80 from $77 at Wedbush
Wedbush raised the firm’s price target on CG Oncology (CGON) to $80 from $77 and keeps an Outperform rating on the shares. The firm notes the company reported first quarter…
CG Oncology price target raised to $96 from $91 at JPMorgan
JPMorgan raised the firm’s price target on CG Oncology (CGON) to $96 from $91 and keeps an Overweight rating on the shares.
CG Oncology price target lowered to $83 from $84 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on CG Oncology (CGON) to $83 from $84 and keeps a Buy rating on the shares. The firm remains positive on…
CG Oncology reports Q1 EPS (71c), consensus (54c)
Reports Q1 revenue $1.08M, consensus $453,030. “We have successfully completed non-clinical and clinical modules for our first BLA submission. The remaining CMC module is progressing as planned, and w...
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
CG Oncology Earnings release: Q1 2026
CG Oncology released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
CG Oncology Quarterly report: Q1 2026
CG Oncology has published its Q1 2026 quarterly earnings report on May 8, 2026.
CG Oncology to Present at Upcoming Investor Conferences in May
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, ...
CG Oncology price target raised to $79 from $73 at RBC Capital
RBC Capital raised the firm’s price target on CG Oncology (CGON) to $79 from $73 and keeps an Outperform rating on the shares. One of the most complex catalysts in…
CG Oncology Proxy statement: Proxy filing
CG Oncology filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
CG Oncology Proxy statement: Proxy filing
CG Oncology filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
JPMorgan ups CG Oncology target, adds ‘Positive Catalyst Watch’
JPMorgan raised the firm’s price target on CG Oncology (CGON) to $91 from $65 and keeps an Overweight rating on the shares. JPMorgan also placed CG on “Positive Catalyst Watch”…